| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
STORY UPDATE
BRISBANE, Calif.—January 9, 2007—InterMune announced it had successfully completed large-scale synthesis and delivery of the API for Hepatitis C virus drug candidate ITMN-191 to Roche. The milestone triggered a $10-million payment from the large pharma.
 
 
BRISBANE, Calif.—InterMune Inc. recently announced an exclusive worldwide agreement to col­laborate with Nutley, N.J.-based Roche on its hepatitis C virus (HCV) protease inhibitor pro­gram.
 
The agreement focuses on InterMune's lead candidate compound, ITMN-191, which is expected to enter clinical tri­als before the end of the year. However, "the value creation potential of this collaboration goes beyond ITMN-191," notes InterMune president and CEO Dan Welch, because the com­panies will also collaborate on a research program to iden­tify, develop and commercialize novel second-generation HCV protease inhibitors.
 
"We had previously commu­nicated that we had planned to continue to develop ITMN-191 without a partner through Phase Ib proof of concept and partner thereafter," Welch notes. "This plan would have put us in a deal around the third or fourth quar­ter of 2007.
 
But InterMune had also noted in corporate communications that it would partner earlier than Phase Ib if it were able to secure "substantially the same terms" that it would have expected at Phase Ib.
 
Under this deal, Roche will exclusively license ITMN-191 and will have the right to exclusively license further HCV protease inhibitor development candidates resulting from the research collab­oration. For ITMN-191, InterMune will conduct Phase I studies, and thereafter Roche will lead clinical development and commercializa­tion. Upon closing, InterMune will receive from Roche an upfront payment of $60 million.
 
In addition, assuming the suc­cessful development and com­mercialization of ITMN-191 in the United States and other coun­tries, InterMune could potentially receive up to $470 million in mile­stone payments, including $35 mil­lion within the next year.
 
"The terms we secured for this collaboration are extremely strong and compare very favorably to programs partnered at Phase I," Welch says. "ITMN-191 is one of several HCV protease inhibitor programs in development, and we recognize that speed to market is one of the most powerful value drivers in our industry."
 
Roche's HCV marketing expertise also loomed large for InterMune. The future HCV mar­ket will be "larger, far more com­plex and far more competitive," Welch notes, and therefore his company needs marketing muscle and know-how on a global scale.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue